For patients with chronic obstructive pulmonary disease, a health management service model using IoT medical devices and IoT wellness devices IoT medical devices and IoT wellness devices, as well as test groups applying IoT medical devices and IoT wellness devices to develop It is divided into a control group that does not apply the group, and measures the lung capacity between the two groups, IoT medical devices and IoT wellness devices. It aims to collect lifelog data through. In addition, we would like to investigate whether monitoring using IoT medical devices and IoT wellness devices and active intervention* based on individual figures are effective in preventing acute exacerbation in patients with metabolic syndrome. 
* Intervention method: alarm message transmission according to the clinical trial compliance level of the test group, regular text service information, bulletin board
Health information using Chronic Obstructive Pulmonary Disease (COPD) is characterized by irreversible airflow restrictions.
It is a lung disease caused by damage to the airways and lungs due to chronic inflammation. 
It is known for external factors such as smoking, air pollution, respiratory infections, genes, age, sex, and respiratory sensitization.
All. COPD, such as high blood pressure, diabetes, and asthma, can reduce symptoms and hospitalization if properly managed in primary care.
It is a representative outpatient sensitive condition (CSC) that may be the cause of death in 2030.
It is the leading cause of death, predicted to be the fourth largest cause of death (Mathers and Loncar, 2006). In Korea, in the last 20 years
It is not consistently included in the top 10 causes of death, and chronic lower respiratory tract diseases ranked 7th among the causes of death in 2013.
W Not only shows a sharp increase, but in 2013, the prevalence of chronic obstructive pulmonary disease in adults over 40
It was 13.5%, and the prevalence also tended to increase with increasing age, and especially in men, the increase was high after their 60s.
While the prevalence rate increases by 2-3% every year, the phosphorus of people diagnosed with chronic obstructive pulmonary disease.
The fate rate was 2.9%, and only 3 out of 100 patients with disease recognized the disease. This low recognition rate is appropriate
Management such as improvement of quality of life, acute deterioration and mortality, as well as relief of symptoms through one prevention and treatment
Even though it is a possible and necessary disease, it may cause the death rate to increase over time.
 In addition, COPD causes a lot of socioeconomic burden. In the case of Korea, according to the Health Insurance Review and Assessment Service in February 2019, about 115.3 billion won (228,000 patients) was spent as direct medical expenses for COPD treatment, and the total number of outpatient specifications If 717,000 cases and medical expenses are about 20.8 billion won, the medical expenses per person is about 140,000 won, an increase of about 8,000 won compared to last year. Among them, acute deterioration is the most significant among COPD-related medical expenses.
It is the largest weight.
However, chronic obstructive pulmonary disease is an Ambulatory Care Sensitive Condition (ACSC) that can prevent exacerbation of the disease and hospitalization if it is effectively treated in an outpatient clinic.
According to the Health Insurance Review and Assessment Service in 2019, patients with chronic obstructive pulmonary disease were found to experience a decrease in the hospitalization experience rate according to constant management (prescription of inhalation bronchodilators, continuous visits, and pulmonary function tests). Appeared to be.
The actual prevalence of COPD was determined by the results of studies conducted using the COPD GOLD criteria (FEV1/FVC<0.7).
While it is generally 10%, in Korea, 13.6% over 40 years old and 30.5% over 65 years old, which is a high level and c

Cohort/Group Label

Among patients with chronic obstructive pulmonary disease, a test group that applied IoT medical devices and IoT wellness devices

Cohort/Group Description

Tests that applied IoT medical devices and IoT wellness devices among 200 subjects eligible for chronic obstructive pulmonary disease 100 people in the military measure lung capacity before and after the clinical trial and collect it, and collect lifelog data of the subject through an APP that can link IoT medical devices and IoT wellness devices.

Cohort/Group Label

Control group who did not apply IoT medical device and IoT wellness device among patients with chronic obstructive pulmonary disease

Cohort/Group Description

Among 200 subjects eligible for chronic obstructive pulmonary disease, 100 control subjects applied IoT medical devices and IoT wellness devices, For comparison, only health information through smart watches and apps is provided.

Not collect nor Archive

Among the residents of Wonju, those with chronic obstructive diseases who visited the Department of Respiratory Medicine in a superior general hospital are adults aged 20 to 80 years old.

This clinical trial is a prospective study, and it is a parallel study in the test group and the control group. Wonju Severance Christian Hospital
Among the patients with chronic obstructive pulmonary disease visiting the outpatient department of inspiratory medicine, Nagun and Da according to the COPD guidelines of the Korean Respiratory Society
Only subjects in the group are recruited, and a test group and a control group are selected after randomization with a 50% probability.

Gender

Age

Description

Selection criteria for test subjects
The diagnosis was confirmed through post-bronchodilator spirometry after administration of bronchodilators in our hospital.
Among the patients, Forced vital capacity (FVC), Forced expiratory volume for 1 second (Forced vital capacity)
Expiratory volume in 1 second; FEV1) and the ratio of the forced expiratory volume to the hard lung capacity for 1 second
Patients who meet the (FEV1/FVC, GOLDb) criteria (less than 0.7) and include the following selection criteria.
-17-
1) Adults 20 to 80 years old
 2) Among the subjects with chronic obstructive pulmonary disease, group Na and group multi according to the COPD guidelines of the Korean Respiratory Society
 3) Outpatient patients in the Department of Respiratory Medicine, Wonju Severance Christian Hospital
 4) Those who consented in writing to this clinical trial
 5) Those who can understand and carry out education and instructions, and can participate in the entire clinical trial period

Exclusion criteria for test subjects
 1) Persons with physical disabilities who cannot wear IoT medical devices and IoT wellness devices
 2) Patients with high reversibility of airflow restrictions
 3) Patients with chronic airway restrictions due to causes other than chronic obstructive pulmonary disease
 (Asthma, patients with predominant asthma, cystic fibrosis, bronchiectasis, closed bronchiolitis, fibrosis due to tuberculosis, etc.
 Patient)
 4) Persons suffering from skin diseases or dysfunctions in the contact area of ​​IoT medical devices
 5) Those who have negative opinions or reluctance to wear IoT medical devices
 6) Subjects who have implanted medical devices in their bodies
 7) pregnant women
 8) Participating in another clinical trial at the same time or taking part in a previous clinical trial
 Those who have not passed (within 3 months)
 9) Subjects judged as inappropriate by the doctor in charge of other examinations

Pulmonary Function Test result

Comparison before and after clinical trials

Number of exacerbations and emergency room visits during the clinical trial participant

Evaluate events within the duration of the clinical trial within one month after the trial